Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK5 | P34947 | 4/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 14/20 | 0.43 |
| ▸ | GRK2 | P25098 | 3/20 | 0.41 |
| ▸ | EIF4E | P06730 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29479792 | 0.92 | GRK5 (0.51) | GRK5PIM1PIM2METGRK2 | |
| SCHEMBL28713867 | 0.92 | GRK5 (0.51) | GRK5PIM1PIM2METGRK2 | |
| SCHEMBL23012096 | 0.87 | GRK5 (0.41) | GRK5PIM1PIM2METGRK2 | |
| SCHEMBL31165961 | 0.87 | GRK5 (0.41) | GRK5PIM1PIM2METGRK2 | |
| SCHEMBL31704583 | 0.86 | KIT (0.46) | PIM1PIM2EIF4EMKNK1MKNK2 | |
| SCHEMBL31165937 | 0.85 | GRK5 (0.44) | GRK5PIM1PIM2METGRK2 | |
| SCHEMBL23033561 | 0.84 | PIM1 (0.55) | PIM1PIM2METALK | |
| SCHEMBL29479735 | 0.82 | S1PR1 (0.41) | GRK5PIM1PIM2MET | |
| SCHEMBL28710692 | 0.82 | S1PR1 (0.41) | GRK5PIM1PIM2MET | |
| SCHEMBL28714669 | 0.81 | PIM1 (0.40) | PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269725-B | Anti-influenza virus compound, preparation method and application thereof | 西藏海思科制药有限公司 | 2024-09-17 | — | — | CN | disclosed |